MarketCapExport financials
Aptose Biosciences (APTO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Aptose Biosciences Balance Sheet 2025-2011 | APTO
Brief overview of Aptose Biosciences's financial position
The comparison uses five available annual reports from the 2020–2024 interval.
The asset base decreased -92%, from $126.3 million to $10.1 million. Resources became smaller over the five periods.
Liabilities expanded faster than the asset base, +99.7% versus -92%. Debt-service capacity deserves attention.
The period ended with negative equity, a structure associated with elevated financial vulnerability.
Net debt moved below zero to -$5.5 million, reflecting surplus cash over debt.
The cash share moved from 93% to 60.7%. A higher figure generally provides more room in an adverse scenario.
The balance sheet carries negative retained earnings of -$541 million. The figure may result from accumulated losses or an active capital return policy.
What the balance sheet shows
Aptose Biosciences's balance sheet looks stretched: reliance on liabilities and a limited capital cushion increase sensitivity to weaker results.
Annual Balance Sheet Aptose Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | -5.53 M | -8.24 M | -35.7 M | -38.5 M | -116 M | -78.3 M | -15.3 M | -10.6 M | -7.93 M | -8.29 M | -17.4 M | -634 K | 563 K | -933 K |
Long Term Debt |
- | 193 K | 621 K | 1 M | 115 K | - | - | - | - | - | - | 487 K | - | - | - |
Long Term Debt Current |
193 K | 428 K | 394 K | 301 K | 459 K | 539 K | 521 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
27.9 M | 10.2 M | 621 K | - | - | 535 K | 1.01 M | - | - | - | - | 487 K | - | - | - |
Total Current Liabilities |
9.31 M | 4.46 M | 15.3 M | 12.3 M | 8.17 M | 6.81 M | 5.54 M | 2.79 M | 1.76 M | - | - | - | - | - | - |
Total Liabilities |
37.2 M | 14.7 M | 15.9 M | 13.3 M | 8.29 M | 7.35 M | 6.55 M | 2.79 M | 1.76 M | 1.32 M | 1.7 M | 2.27 M | 1.76 M | 2.62 M | 1.19 M |
Retained Earnings |
-566 M | -541 M | -516 M | -464 M | -423 M | -357 M | -302 M | -276 M | -247 M | -187 M | -168 M | -194 M | -194 M | -189 M | -194 M |
Total Assets |
10 M | 10.1 M | 13 M | 51 M | 82.5 M | 126 M | 100 M | 16.9 M | 12 M | 8.64 M | 15.3 M | 28.5 M | 1 M | 648 K | 2.05 M |
Cash and Cash Equivalents |
935 K | 6.15 M | 9.25 M | 37 M | 39.1 M | 117 M | 79.8 M | 15.3 M | 10.6 M | - | - | - | - | - | - |
Book Value |
-27.2 M | -4.54 M | -2.9 M | 37.7 M | 74.2 M | 119 M | 93.9 M | 14.1 M | 10.2 M | 7.32 M | 13.6 M | 26.2 M | -758 K | -1.97 M | 865 K |
Total Shareholders Equity |
-27.2 M | -4.54 M | -2.9 M | 37.7 M | 74.2 M | 119 M | 93.9 M | 14.1 M | 10.2 M | 7.33 M | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Aptose Biosciences
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | 80 K | 193 K | - | 414 K | 520 K | 621 K | 720 K | 817 K | 918 K | 1 M | 1 K | - | 10 K | 115 K | 218 K | 321 K | 420 K | 535 K | 535 K | 535 K | 535 K | 1.01 M | 1.01 M | 1.01 M | 1.01 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
34.2 M | 18.7 M | 11 M | 8.54 M | 10.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
45.4 M | 25.8 M | 20 M | 14.9 M | 14.7 M | - | 13.1 M | 12.7 M | 15.9 M | 13.1 M | 12.8 M | 13.3 M | 13.3 M | 10.2 M | - | 7.32 M | 8.29 M | 8.52 M | 8.03 M | 5.79 M | 7.35 M | 7.35 M | 7.35 M | 7.35 M | 6.55 M | 6.55 M | 6.55 M | 6.55 M | 2.79 M | 2.79 M | 2.79 M | 2.79 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-574 M | -559 M | -554 M | -547 M | -541 M | - | -532 M | -525 M | -516 M | -504 M | -492 M | -478 M | -464 M | -454 M | - | -434 M | -423 M | -398 M | -387 M | -373 M | -357 M | -357 M | -357 M | -357 M | -302 M | -302 M | -302 M | -302 M | -276 M | -276 M | -276 M | -276 M | -247 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
10.7 M | 6.34 M | 5.59 M | 7.47 M | 10.1 M | - | 10.9 M | 12.8 M | 13 M | 20.9 M | 26.6 M | 39.3 M | 51 M | 57 M | - | 72.6 M | 82.5 M | 97.2 M | 106 M | 115 M | 126 M | 126 M | 126 M | 126 M | 100 M | 100 M | 100 M | 100 M | 16.9 M | 16.9 M | 16.9 M | 16.9 M | 12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
1.02 M | 613 K | 553 K | 4.74 M | 6.15 M | - | 8.33 M | 7.35 M | 9.25 M | 15.7 M | 8.4 M | 22.8 M | 37 M | 28 M | - | 37 M | 39.1 M | 75.1 M | 83.3 M | 87.1 M | 117 M | 117 M | 117 M | 117 M | 79.8 M | 79.8 M | 79.8 M | 79.8 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 10.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
-34.7 M | -19.4 M | -14.4 M | -7.39 M | -4.54 M | - | -2.18 M | 137 K | -2.9 M | 7.78 M | 13.8 M | 26 M | 37.7 M | 46.8 M | - | 65.3 M | 74.2 M | 88.7 M | 98.2 M | 109 M | 119 M | 119 M | 119 M | 119 M | 93.9 M | 93.9 M | 93.9 M | 93.9 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-34.7 M | -19.4 M | -14.4 M | -7.39 M | -4.54 M | -9.13 M | -2.18 M | 137 K | -2.9 M | 7.78 M | 13.8 M | 26 M | 37.7 M | 46.8 M | 55.5 M | 65.3 M | 74.2 M | 88.7 M | 98.2 M | 109 M | 119 M | 119 M | 119 M | 119 M | 93.9 M | 93.9 M | 93.9 M | 93.9 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 10.2 M | 9.82 M | 10.3 M | 7.77 M | 7.33 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Aptose Biosciences, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Biotechnology
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
BioLineRx Ltd.
BLRX
|
$ 2.32 | 2.67 % | $ 5.72 B |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
$ 60.0 | 0.22 % | $ 11.5 B |  USA |
 |
Bristol-Myers Squibb Company
BMY
|
$ 62.4 | 0.19 % | $ 127 B | USA |
 |
Benitec Biopharma
BNTC
|
$ 10.0 | 2.56 % | $ 466 M | USA |
 |
BioNTech SE
BNTX
|
$ 98.3 | 0.02 % | $ 23.8 B |  Germany |
 |
Burford Capital Limited
BUR
|
$ 3.92 | 0.51 % | $ 859 M |  Britain |
 |
BeyondSpring
BYSI
|
$ 0.77 | 2.15 % | $ 31.7 M | USA |
 |
Cabaletta Bio
CABA
|
$ 1.92 | 0.75 % | $ 193 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 2.2 | 0.92 % | $ 3.62 M | Israel |
 |
Capricor Therapeutics
CAPR
|
$ 9.47 | 10.5 % | $ 440 M | USA |
 |
Catalyst Biosciences
CBIO
|
$ 14.59 | 1.58 % | $ 1.3 B | USA |
 |
C4 Therapeutics
CCCC
|
$ 3.33 | 6.39 % | $ 276 M | USA |
 |
Codexis
CDXS
|
$ 1.39 | 2.96 % | $ 121 M | USA |
 |
Cerus Corporation
CERS
|
$ 2.38 | 0.82 % | $ 454 M | USA |
 |
Certara
CERT
|
$ 9.2 | 0.11 % | $ 1.48 B | USA |
 |
Cullinan Management
CGEM
|
$ 15.35 | 0.79 % | $ 925 M | USA |
 |
Compugen Ltd.
CGEN
|
$ 2.38 | 1.28 % | $ 222 M | Israel |
 |
Coherus BioSciences
CHRS
|
$ 1.21 | 2.54 % | $ 142 M | USA |
 |
Celldex Therapeutics
CLDX
|
$ 32.41 | 2.43 % | $ 2.15 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
$ 3.78 | 0.13 % | $ 46.1 M | Israel |
 |
Cellectis S.A.
CLLS
|
$ 1.51 | 2.72 % | $ 151 M |  France |
 |
Cellectar Biosciences
CLRB
|
$ 1.84 | 1.1 % | $ 4.8 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
$ 5.3 | 8.0 % | $ 2.35 M | USA |
 |
Cocrystal Pharma
COCP
|
$ 1.15 | 2.68 % | $ 13 M | USA |
 |
Collegium Pharmaceutical
COLL
|
$ 21.82 | 0.44 % | $ 691 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
$ 115.23 | 0.43 % | $ 12 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
$ 6.82 | 2.87 % | $ 90.8 M | USA |
 |
Cardiff Oncology
CRDF
|
$ 1.21 | 3.42 % | $ 80.9 M | USA |
 |
Curis
CRIS
|
$ 0.84 | 1.21 % | $ 11.1 M | USA |
 |
CorMedix
CRMD
|
$ 7.7 | 0.51 % | $ 555 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
$ 55.32 | 0.02 % | $ 4.97 B |  Schweiz |
 |
Corvus Pharmaceuticals
CRVS
|
$ 11.52 | 0.85 % | $ 910 M | USA |
 |
Champions Oncology
CSBR
|
$ 5.0 | 4.38 % | $ 69.2 M | USA |
 |
CytomX Therapeutics
CTMX
|
$ 2.72 | 2.23 % | $ 375 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
$ 0.53 | 0.41 % | $ 5.86 M | USA |
 |
Cue Biopharma
CUE
|
$ 25.87 | 1.41 % | $ 2.45 B | USA |
 |
CEL-SCI Corporation
CVM
|
$ 2.06 | 15.73 % | $ 16.5 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
$ 65.91 | 0.41 % | $ 7.92 M | USA |
 |
Daré Bioscience
DARE
|
$ 0.85 | 4.7 % | $ 9.5 M | USA |
 |
DBV Technologies S.A.
DBVT
|
$ 11.76 | 1.82 % | $ 1.64 B | France |
 |
DiaMedica Therapeutics
DMAC
|
$ 8.27 | 0.85 % | $ 389 M | USA |
 |
Denali Therapeutics
DNLI
|
$ 20.67 | 0.38 % | $ 3.57 B | USA |
 |
Precision BioSciences
DTIL
|
$ 6.26 | 1.29 % | $ 80.3 M | USA |
 |
Dyadic International
DYAI
|
$ 0.44 | 0.49 % | $ 15.9 M | USA |
 |
Editas Medicine
EDIT
|
$ 2.57 | 0.19 % | $ 228 M | USA |
 |
Edesa Biotech
EDSA
|
$ 4.21 | 18.26 % | $ 23.9 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
$ 0.5 | 4.73 % | $ 22.8 M | Israel |
 |
Enanta Pharmaceuticals
ENTA
|
$ 13.18 | 4.27 % | $ 281 K | USA |
 |
Entera Bio Ltd.
ENTX
|
$ 2.91 | 8.18 % | $ 134 M | Israel |
 |
Equillium
EQ
|
$ 1.63 | 0.31 % | $ 93.4 M | USA |